HOME >> BIOLOGY >> NEWS
New antibacterials being developed to tackle MRSA superbug

A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need.

Prolysis, an R&D company based in Oxford, has received one of three inaugural Seeding Drug Discovery awards for its new antibacterial compounds aimed at tackling life-threatening, drug-resistant infections caused by staphylococci, including MRSA.

The bacterium Staphylococcus aureus can infect wounds, including those resulting from medical procedures conducted in hospitals. It may then spread further into the body and cause serious infections such as blood poisoning. Methicillin-resistant Staphylococcus aureus, or MRSA, is a form of the bacterium that is resistant to the drug methicillin and a number of other antibiotics and tends to be more difficult to treat.

"The so-called superbug MRSA is fast becoming untreatable with the currently available antibiotics," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "We urgently need a new generation of antibacterial medicines to stop its spread through hospitals, nursing homes and the wider community."

The compounds being developed by Prolysis under the award from the Wellcome Trust block the ability of the MRSA bacteria to divide and multiply. They do this by inhibiting the function of the bacterium's FtsZ protein, which is essential for cell division. FtsZ is not found in humans so targeting a unique protein like this should reduce the likelihood of side-effects in patients. Because of the novel mode of action of the new class of compounds, the levels of resistance in the bacterial population should be extremely low if a new drug was to emerge from this programme.

"The antibiotic that we are developing is far more selective than those currently in use, targeting only staphylococcal infections," says Dr Lloyd
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
14-Jan-2007


Page: 1 2

Related biology news :

1. Universal flu vaccine being tested on humans
2. Reproductive speed protects large animals from being hunted to extinction
3. DNA layer reduces risk of reserve parts being rejected
4. Are scientists making progress in being able to regenerate bone tissue?
5. Its not easy being green
6. Its not easy being green
7. Accelerating loss of ocean species threatens human well-being
8. Accelerating loss of ocean species threatens human well-being
9. Fat stem cells being studied as option for breast reconstruction
10. Nanotechnology being used to improve biocompatibility of human prosthetics and implants
11. Progress being made in exploring potential use of stem cells to treat heart disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2019)... ... , ... In the development of biosimilars, the broad definition of the similarity ... this uncertainty, several manufacturers have been successful and numerous follow-on biologics are approved in ... learn how analytical similarity is achieved in biosimilars based on recently approved products in ...
(Date:3/27/2019)... ... March 26, 2019 , ... Evan Holden , a ... LLP , was a panelist at the National Academy of Sciences (NAS) Roundtable on ... Holden, a member of the firm’s award-winning Pharmaceutical, Medical Device & Health Care ...
(Date:3/25/2019)... ... March 25, 2019 , ... Researchers have found ... technology since it came into use by the scientific community. Keck Graduate Institute ... the first to combine the power of CRISPR’s nucleic acid targeting with the ...
Breaking Biology News(10 mins):
(Date:4/10/2019)... ... April 10, 2019 , ... After more than three months of renovation, Lajollacooks4u ... equipped with updated appliances and modern lighting and fixtures, and will provide additional workspace ... “We’ve seen tremendous growth in the demand for our team-building events and cooking classes ...
(Date:4/8/2019)... ... , ... US Capital Global Securities , an affiliate of US Capital ... privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of drugs ... dysfunction disorder and is ready to begin phase 2b trials. In phase 2a trials, ...
(Date:3/27/2019)... POWAY, Calif. (PRWEB) , ... March 26, 2019 , ... ... autologous adipose-derived stem cell services to veterinarians across the United States and Canada since ... well as bone and soft tissue injuries in the dog, cat, and horse. ...
(Date:3/19/2019)... , ... March 19, 2019 , ... The AACR annual ... great opportunity to see the most cutting-edge cancer research. The Visikol team will be ... 3D cell culture assays as well as their digital pathology services . ...
Breaking Biology Technology:
Cached News: